

Supplementary material has been published as submitted. It has not been copyedited or typeset by Scandinavian Journal of Urology

Table SI. Procedures for LUTS included in the study

Surgical procedure	Nordic Classification of Surgical Procedures
Distension of bladder with fluid	KCV04
Urinary bladder endoscopic botulin therapy	KCV12
Transvesical prostatectomy	KED00
Retropubic prostatectomy	KED10
Transurethral resection of prostate (TURP)	KED22
Transurethral incision of prostate (TUIP)	KED33
Visual laser resection of prostate	KED52
Transurethral needle ablation of prostate (TUNA)	KED62
Transurethral microwave therapy of prostate (TUMT)	KED72
Transurethral electrovaporization of the prostate (TUVP)	KED76
Percutaneous cryotherapy of prostate	KED80
Other partial excision of prostate	KED96
Other transurethral partial excision of prostate	KED98

Table SII. Predictors of bother among men with persistent mild urgency at follow-up – logistic regression

	Bother ≥ 2 DAN-PSS pts at follow-up		Odds ratio				<i>p</i>
	%	95% CI	Unadjusted		Adjusted		
			OR	95% CI	OR	95% CI	
All (n=1056)	5.9	4.5-7.3					
Age 50-60^a	5.9	4.0-7.8	1.0	0.6-1.7	0.8	0.4-1.7	
Age 70-80^a	6.9	3.1-10.6	1.2	0.6-2.4	0.6	0.2-1.5	
Single or widowed	6.5	3.5-9.6	1.2	0.6-2.1	1.3	0.7-2.3	
Obesity^b	3.5	0.9-6.1	0.5	0.2-1.2	0.5	0.2-1.2	
Smoking^c	3.4	0.7-6.1	0.5	0.2-1.2	0.6	0.2-1.5	
Diabetes	7.7	3.3-12.2	1.4	0.7-2.8	1.1	0.5-2.4	
Hypertension	6.5	4.3-8.8	1.2	0.7-2.1	1.2	0.6-2.1	
Cardiac dis.	9.4	5.5-13.2	2.0	1.1-3.5	1.9	1.0-3.5	0.053
Pulmonary dis.	10.4	5.2-15.7	2.1	1.0-4.1	2.0	1.0-4.0	0.036
Cerebrovasc. dis.	8.5	1.2-15.8	1.5	0.5-4.0	1.1	0.4-3.1	
Neurologic dis.	7.1	0.2-14.1	1.2	0.3-3.6	1.2	0.4-3.5	
Cancer	6.3	1.7-10.9	1.1	0.4-2.5	0.7	0.3-1.7	
Depression	8.7	3.5-13.9	1.6	0.7-3.4	1.4	0.7-3.1	
LUTS medication^d	10.5	6.9-14.1	2.7	1.5-4.6	2.7	1.5-4.9	0.001
LUTS operation^e	5.0	0.0-12.1	0.8	0.1-3.4	0.4	0.1-1.9	

^a Age at baseline, reference group aged 30-40, ^b BMI ≥ 30 at follow-up, ^c current smoker at follow-up, ^d includes alpha-blockers, 5-alpha reductase inhibitors and anticholinergics, no initiations of mirabegron as first-line treatment during the follow-up (not available until 2013), ^e endoscopic and surgical procedures during the follow-up for benign prostatic hyperplasia and overactive bladder listed in Table SI.

Table SIII. Predictors of urgency at follow-up – logistic regression

	Urgency ≥ 2 DAN-PSS pts at follow-up		Odds ratio				<i>p</i>
	%	95% CI	Unadjusted	Adjusted	OR	95% CI	
All (n=2480)	13.4	12.1-14.8					
Age 50-60^a	14.9	12.9-16.9	1.3	1.0-1.6	1.5	1.1-2.1	0.017
Age 70-80^a	23.5	19.3-27.7	2.4	1.8-3.1	1.8	1.2-2.9	0.008
Single or widowed	17.7	14.6-20.7	1.6	1.2-2.0	1.4	1.0-1.8	0.022
Obesity^b	15.1	11.9-18.2	1.2	0.9-1.6	1.1	0.8-1.5	
Smoking^c	14.0	10.6-17.4	1.1	0.8-1.5	1.1	0.8-1.6	
Diabetes	19.8	15.6-24.1	1.7	1.3-2.4	1.0	0.7-1.4	
Hypertension	17.8	15.5-20.1	1.9	1.5-2.4	1.2	0.9-1.5	
Cardiac dis.	22.2	18.5-25.9	2.3	1.7-2.9	1.2	0.9-1.7	
Pulmonary dis.	25.0	20.3-29.7	2.5	1.9-3.4	1.6	1.2-2.2	0.002
Cerebrovasc. dis.	30.7	23.2-38.1	3.1	2.1-4.6	2.0	1.3-3.0	0.001
Neurologic dis.	30.7	23.3-38.1	3.2	2.1-4.6	1.9	1.3-2.9	0.002
Cancer	20.6	15.5-25.6	1.8	1.3-2.5	0.9	0.6-1.3	
Depression	25.9	20.9-30.9	2.6	1.9-3.5	2.2	1.6-3.1	<0.001
LUTS medication^d	27.5	23.9-31.1	3.8	3.0-4.9	2.9	2.2-3.8	<0.001
LUTS operation^e	24.7	15.3-34.1	2.2	1.3-3.7	0.9	0.5-1.5	

^a Age at baseline, reference group aged 30-40, ^b BMI ≥ 30 at follow-up, ^c current smoker at follow-up, ^d includes alpha-blockers, 5-alpha reductase inhibitors and anticholinergics, no initiations of mirabegron as first-line treatment during the follow-up (not available until 2013), ^e endoscopic and surgical procedures during the follow-up for benign prostatic hyperplasia and overactive bladder listed in Table SI.